UNITED STATES
                     SECURITIES AND EXCHANGE  COMMISSION
                                 Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)    March 30, 2006

                          MEDISCIENCE TECHNOLOGY CORP.

--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

        NEW JERSEY                      0-7405                   22-1937826

--------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
       of incorporation)              File Number)           Identification No.)


1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey            08034
--------------------------------------------------------------------------------
        (Address of principal executive offices)                    (Zip Code)

Registrant's telephone number, including area code (215) 485 0362

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2- below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17
    CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13 e-4(c) under the
    Exchange Act (17 CFR 240.13 e-4(c))

<PAGE>

Item  8.01. Other Events.

On April 3, 2006 Mediscience Technology, Corp. (OTCBB:MDSC.OB) announced The
Food and Drug Administration on March 29, 2006 approved as a "Non-significant
risk device study the Company's multi-center pilot study to establish the safety
and parameters of efficacy of its proprietary Optical Biopsy Device (CD-R) for
cancer detection of the cervix preliminary to a pivotal study" expected to bring
this molecular algorithmic specific technology to market. This disclosure is
intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7
and 7.0 as well as all applicable and presently effective Sarbanes-Oxley
disclosure requirements under Regulation G.


Item 9.01. Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release of Mediscience Technology Corp. dated April 3, 2006



                                   SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized on April 3, 2006

                                             MEDICSCIENCE TECHNOLOGY CORPORATION

                                             By:  Peter Katevatis
                                                  ------------------------------
                                             Name: Peter Katevatis
                                             Title: Chairman of the Board and
                                                    Chief Executive Officer


                                                                               2
<PAGE>


                                  Exhibit Index

Exhibit No.   Description
-----------   ------------------------------------------------------------------

99.1          Press Release of Mediscience Technology Corp. dated  April 3, 2006







                                                                               3